AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 84.34% | -64.48% | 23.88% | -33.36% | 33.06% |
| Total Depreciation and Amortization | 9.45% | 2.49% | 6.89% | 136.49% | -147.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.96% | 27.87% | -29.03% | -42.20% | 384.39% |
| Change in Net Operating Assets | -154.83% | -7.95% | -260.58% | -29.78% | 360.10% |
| Cash from Operations | 33.94% | -62.31% | -180.46% | -44.43% | 72.30% |
| Capital Expenditure | -10.25% | 33.20% | -25.66% | 31.95% | 15.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 87.12% | 346.21% | -199.33% | -63.82% | 131.08% |
| Cash from Investing | 105.93% | 214.70% | -500.89% | -77.77% | 865.47% |
| Total Debt Issued | 39.32% | 37.22% | -10.46% | 42.35% | 29.74% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,421.43% | 97.95% | -4,888.76% | -0.56% | 3.80% |
| Cash from Financing | -44.18% | 318.43% | -156.53% | 44.13% | 31.70% |
| Foreign Exchange rate Adjustments | 153.31% | -171.48% | 28.98% | 127.31% | -688.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 582.86% | 86.12% | -2,372.32% | -90.09% | 236.97% |